Evidence map›Paper›PMID 35205686›Full record

ArticleCancers2022

A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes.

Kaley E Woods, Ting Martin Ma, Kiri A Cook, Eric D Morris, Yu Gao, Ke Sheng, Amar U Kishan, John V Hegde, Carol Felix, Vincent Basehart and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Kaley E WoodsDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-6189-0313
Ting Martin MaDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-0053-7874
Kiri A CookDepartment of Radiation Oncology, Oregon Health & Science University, Portland, OR 97239, USA.
Eric D MorrisDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Yu GaoDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Ke ShengDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
John V HegdeDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Carol FelixDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Vincent BasehartDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kelsey NaraharaDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Zhouhuizi ShenDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Stephen TennDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0001-8748-1676
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Robert K ChinDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Minsong CaoDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USOregon Health & Science University · USUniversity of Southern California · US

Funding

Varian Medical Systems (United States) NCT03892720
6 · The paper itself

Abstract

This study reports the initial results for the first 15 patients on a prospective phase II clinical trial exploring the safety, feasibility, and efficacy of the HyperArc technique for recurrent head and neck cancer treatment. Eligible patients were simulated and planned with both conventional VMAT and HyperArc techniques and the plan with superior dosimetry was selected for treatment. Dosimetry, delivery feasibility and safety, treatment-related toxicity, and patient-reported quality of life (QOL) were all evaluated. HyperArc was chosen over conventional VMAT for all 15 patients and enabled statistically significant increases in dose conformity (R50% reduced by 1.2 ± 2.1,

Indexed as

HyperArcnon-coplanar VMATrecurrent head and neck cancerreirradiationSBRT

Identifiers

PMID35205686
PMCPMC8870161
OpenAlexW4213351092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.